title: Aprotinin and renal dysfunction.
abstract: Aprotinin is a polypeptide serine protease inhibitor used to prevent bleeding and need for transfusions in patients having heart surgery. A recent analysis of an observational study data set suggested the use of aprotinin was associated with an increased risk of developing renal failure. The present article reviews the data from basic science studies in tissues, animals and man together with the data from observational studies and randomised controlled trials. The interpretation of the data is hampered owing to the use of different endpoints to describe mild/moderate renal impairment. Nonetheless, the evidence points to aprotinin use being associated with a transient small rise in plasma creatinine concentration in certain patients. There is no evidence for an increased risk of developing new renal failure requiring dialysis/renal replacement therapy.
authors.affiliation: Royal Brompton and Harefield NHS Trust, Harefield Hospital, Hill End Road, Harefield, UB9 6JH, UK.
authors.forename: Marie
authors.initials: M
authors.lastname: Bosman
authors.forename: David
authors.initials: D
authors.lastname: Royston
mesh_terms: D000818:Animals; D007611:Aprotinin / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D006348:Cardiac Surgical Procedures / Q000379:methods; D003404:Creatinine / Q000097:blood; D006490:Hemostatics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007677:Kidney Function Tests; D016032:Randomized Controlled Trials as Topic; D051437:Renal Insufficiency / Q000139:chemically induced*; D012307:Risk Factors; D015842:Serine Proteinase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D006490:Hemostatics; D015842:Serine Proteinase Inhibitors; D007611:Aprotinin; D003404:Creatinine